Impact of Rituximab Treatment on 90Y-Ibritumomab Dosimetry for Patients with Non-Hodgkin Lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Impact of Rituximab Treatment on 90Y-Ibritumomab Dosimetry for Patients with Non-Hodgkin Lymphoma

Published:2009-12-15 Issue:1 Volume:51 Page:150-157
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Shen Sui,Forero Andres,Meredith Ruby F.,Shah Jatin J.,Knox Susan J.,Wiseman Gregory A.,Usrey Marc E.,LoBuglio Albert F.

Publisher

Society of Nuclear Medicine

Subject

Radiology Nuclear Medicine and imaging

Reference37 articles.

1. Cancer statistics, 1996

2. Follicular lymphoma: prognostic factors for response and survival.

3. Foon K, Fisher R. Lymphomas. In: Beutler E, Lichtman M, Coller B, et al., eds. Williams Hematology. 5th ed. New York, NY: McGraw-Hill, Inc.; 1993.

4. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dosimetric analysis of 177Lu-DOTA-rituximab in patients with relapsed/refractory non-Hodgkin’s lymphoma;Nuclear Medicine Communications;2016-07

2. Phase I Study of a Modified Regimen of 90Yttrium–Ibritumomab Tiuxetan for Relapsed or Refractory Follicular or Transformed CD20+ Non-Hodgkin Lymphoma;Cancer Biotherapy and Radiopharmaceuticals;2013-06

3. An update on radioimmunotherapy for lymphoma;International Journal of Hematologic Oncology;2013-04

4. Perspective: Multimodality Radionuclide Therapy of Progressive Disseminated Lymphoma and Neuroendocrine Tumors as a Paradigm for Cancer Control;Cancer Biotherapy and Radiopharmaceuticals;2012-11

5. Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin’s lymphoma using 89Zr-ibritumomab tiuxetan and PET;European Journal of Nuclear Medicine and Molecular Imaging;2012-01-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3